RxDoctor Payments Data

Susan Holmes

Primary Care · Opelika, ALNPI 1396826251

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 33.2% of the total.

$2,913in general payments, 2019–2025

Across 176 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$967
  • AbbVie$545
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$334
  • Evoke Pharma, Inc.$201
  • Phathom Pharmaceuticals, Inc.$156
  • Janssen Scientific Affairs, LLC$125
  • plus $585 from 17 others

What the payments were for

  • Food & beverage$2,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,913 in reported general payments places this provider in the 75th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$4,944
Medicare patients
37
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$70,927
OzempicSemaglutide21$20,832
Pantoprazole Sodium206$2,895
Levothyroxine Sodium75$1,738
Budesonide DrBudesonide13$1,695
Omeprazole78$1,423
Atorvastatin Calcium67$976
Valsartan18$904
Losartan Potassium60$815
Simvastatin49$621
Amlodipine Besylate83$559
LoperamideLoperamide Hcl23$556
Rosuvastatin Calcium21$535
Metformin Hcl ErMetformin Hcl28$531
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide32$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$334$70,92722 claims
Novo NordiskOzempic$28$20,83221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 159 primary care providers in Alabama.

Other primary care in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →